MADRIGAL PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
Pre-market 08:46:25 am | |||
| 218 USD | -7.48% |
|
215.8 | -0.99% |
| May. 07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
| May. 07 | Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 81.08M | Sales 2025 * | 362M | Capitalization | 4.64B |
|---|---|---|---|---|---|
| Net income 2024 * | -559M | Net income 2025 * | -370M | EV / Sales 2024 * | 56.1 x |
| Net cash position 2024 * | 93.53M | Net Debt 2025 * | 116M | EV / Sales 2025 * | 13.1 x |
| P/E ratio 2024 * |
-7.86
x | P/E ratio 2025 * |
-14
x | Employees | 376 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Madrigal Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -7.48% | ||
| 1 week | +6.83% | ||
| Current month | +6.83% | ||
| 1 month | -10.32% | ||
| 3 months | +15.60% | ||
| 6 months | +43.29% | ||
| Current year | -5.80% |
1 week
208.77
236.65
1 month
189.00253.48
Current year
168.25299.98
1 year
119.76311.56
3 years
52.33322.67
5 years
52.33322.67
10 years
6.60325.98
| Managers | Title | Age | Since |
|---|---|---|---|
Edward Chiang
FOU | Founder | - | 11-08-31 |
William Sibold
CEO | Chief Executive Officer | - | 23-09-07 |
Rebecca Taub
FOU | Founder | 71 | 16-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 78 | 11-08-31 | |
Julian Baker
CHM | Chairman | 57 | 23-06-14 |
Ken Bate
BRD | Director/Board Member | 73 | 16-07-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.35% | 0 M€ | 0.00% | - | |
| 0.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 218 | -7.48% | 780,739 |
| 24-05-06 | 235.6 | +2.49% | 423,461 |
| 24-05-03 | 229.8 | +6.38% | 441,775 |
| 24-05-02 | 216 | +2.59% | 451,720 |
| 24-05-01 | 210.6 | +3.22% | 427,526 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotes
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
218
USD
Average target price
371.8
USD
Spread / Average Target
+70.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.80% | 4.64B | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +8.88% | 23.47B | |
| -13.89% | 21.9B | |
| -5.89% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- MDGL Stock